Which of the following inhalers is commonly prescribed for chronic obstructive pulmonary disease?

Long-acting beta-agonists (LABAs) are commonly prescribed for chronic obstructive pulmonary disease (COPD) because they work by stimulating beta-2 receptors in the lungs, leading to bronchodilation and improved airflow. These medications have a prolonged duration of action, typically lasting 12 hours or more, which makes them particularly effective for managing chronic conditions like COPD. Patients often use LABAs as maintenance therapy to help control symptoms and prevent exacerbations.

In the context of COPD management, LABAs are frequently used in conjunction with inhaled corticosteroids to provide a comprehensive approach to treatment. This combination helps reduce airway inflammation and facilitates better overall control of the disease.

While other options may play a role in the management of respiratory conditions, they are not as commonly prescribed as LABAs for the ongoing treatment of COPD. For example, short-acting beta-agonists are typically used for quick relief but are not ideal for long-term management, leukotriene inhibitors are more often associated with asthma treatment, and anticholinergics, while also effective in COPD, are not the primary medication compared to LABAs in many treatment plans. Therefore, LABAs are a cornerstone in the management of COPD, emphasizing their essential role in enhancing the quality